Medistim ASA has transferred 9.000 shares toMedistim CEO,Kari E. Krogstad , at the last traded share price in 2023, of214 NOK per share. This is in accordance with her compensation agreement with the company, as described in the Company's Annual Report. After the transfer,Kari E. Krogstad holds a total of 47.083 shares. According to the CEO's share program she is entitled to receiving another 7.500 shares if in position 1st ofJanuary 2025 and another 8.000 shares if in position 1st ofJanuary 2026 . A new agreement is entered between the company and the CEO, related to this share program. The CEO 100% owned company, K2 Consulting AS, has purchased the shares fromMedistim ASA with a lock in period of 1 year for the 7.500 shares and a lock in period of 2 years for the 8.000 shares. The lock in period of 1 year qualifies for a 14 % share price discount and the 2 year lock in period qualifies for an 18% discount. Average share price in the 14 days subscription period wasNOK 216 per share. 7.500 shares was therefore purchased atNOK 185,83 per share and 8.000 shares was purchased atNOK 177,19 per share. To finance the purchase,Medistim has given the CEO a loan and when the lock in period has ended, she is given a bonus equal to the loan amount. K2 Consulting AS has in total purchased 15.500 shares at an average price ofNOK 181,37 per share. After the purchase K2 Consulting AS holds 15.500Medistim shares. After these transactionsKari E. Krogstad controls in total 62.583Medistim shares.Medistim ASA has 31.117 own shares after the transactions.
Click here for more information
© Oslo Bors ASA, source